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aCL - anti-cardiolipin 
ACR - American College of Rheumatology 
AECC - American-European Consensus Criteria 
AGSE - peptide aa184-227 from the second extracellular loop of the m3AChR 
ANA - antinuclear antibody 
anti-MCV - anti-mutant citrullinated vimentin 
anti-RNP - anti-ribonucleoprotein 
anti-Sm - anti-Smith 
anti-SSA - anti-Sjögren’s syndrome A 
anti-SSB - anti-Sjögren’s syndrome B 
APA – antiphospholipid antibody 
APC - antigen presenting cell 
APS - antiphospholipid syndrome 
aß2GPI - anti-beta2glycoprotein I 
BAGSE - BSA-AGSE multiple-conjugated peptide 
BSA - bovine serum albumin 
C3 - complement 3 
C4 – complement 4 
CMV - cytomegalovirus  
DNA – desoxiribonucleic acid (ds – double stranded) 
EBV - Epstein-Barr virus  
ELISA – enzyme-linked immunosorbent assay 
ESR - erythrocyte sedimentation rate 
FACIT - Functional Assessment of Chronic Illness Therapy 
FcRγ – Fc receptor γ 
FCS - foetal calf serum 
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RA - rheumatoid arthritis 
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RF - rheumatoid factor 
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1. Introduction 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by 
disorders of both the cellular and humoral immune responses, production of autoantibodies 
and formation of immune complexes leading to a diverse array of clinical manifestations. It is 
a multisystem disease involving the immune-mediated inflammation in multiple organs 
affecting predominantly the joints, kidneys, mucocutaneous and nervous system and causing 
haematological abnormalities. The course of the disease is tipified by exacerbations and 
remissions. The severity of the clinical picture is greatly affected by the number and nature of 
the various organ manifestations, while the mortality of patients with SLE is still remarkable. 
Fatal outcome is not only the result of lupus activity when vital organs are involved, but also 
the complications of immunosuppressive treatment, in particular infections, or the long-term 
complications such as cardiovascular disease.(1, 2). 
SLE afflicts mainly women, with the ratio of 9:1 compared with men. The disease can 
develop at any age with varying characteristics (3). Typically, the manifestation of the disease 
tends to be more acute in those of younger age. However, patients with late onset lupus have a 
much higher mortality rate, nearly 50% of them die due to complications of infection. This is 
most likely the impact of older age, since the manifestation of their disease is usually less 
severe than in younger patients. Women of childbearing age are at particular risk of the 
development of SLE. 
The diagnosis of SLE is established on expert opinion and is aided by the latest 
classification criteria of the Systemic Lupus Collaborating Clinics (SLICC), who revised and 
validated the American College of Rheumatology (ACR) SLE classification criteria in 2012 
(4, 5). From the seventeen identified SLICC criteria, the diagnosis of SLE requires either the 
fulfillment of at least four criteria, with at least one clinical and one immunologic criterion, or 
lupus nephritis as the sole clinical criterion in the presence of antinuclear antibody (ANA) or 
anti-dsDNA antibodies. Although SLE usually occurs alone, many patients have symptoms 
characteristic of one or more of other connective tissue diseases, such as Sjögren’s syndrome 
(SS), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), scleroderma, 
polymyositis-dermatomyositis, and various forms of vasculitis. An overlap diagnosis can be 
made when a patient meets the official criteria for two or possibly more autoimmune diseases. 
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The complex etiopathogenesis of SLE still remains elusive (6,7). Various genetic, 
environmental and immunomodulatory factors contribute to the expression of SLE. The 
already identified heritable factors associated with SLE include the combined effect of genes 
that are involved in nucleic acid sensing, interferon production, antigen-presentation (HLA-
associations), and in T or B cell signaling pathways. Epigenetic changes such as DNA 
hypomethylation in CD4 T cells also play an important role in the regulation of gene 
expression. Exposure to ultraviolet light, various environmental toxins (e.g. smoking), viral 
infections including parvovirus B19, cytomegalovirus (CMV), and Epstein-Barr virus (EBV) 
are known risk factors. Pathogen-associated nucleic acids can exacerbate SLE pathology 
through stimulation of Toll-like receptors (TLRs), moreover, the discrimination by TLRs 
between pathogenic and self nucleic acids is not perfect, thus endogenous nucleic acids of 
apoptotic cells and necrotic debris may also activate TLRs. 
The immune system is broadly compromised in patients with SLE, and the 
dysregulation of single elements induces further, multiple alterations at virtually every 
component of the system. A central role for T cells is suggested in the pathogenesis of the 
disease, and intrinsic aberrations of SLE T cells are considered to be the major factor in the 
pathologic process (7-9). An important step is the enhanced T cell activation due to abnormal 
antigen presenting cell (APC) function. Multiple activation and signaling defects have been 
reported in SLE T cells. The key players in the enhanced early signaling are the altered T cell 
receptor/CD3 complexes (CD3ζ is replaced by the FcRγ chain, that associates with Syk 
kinase), and the aggregation of lipid rafts on the cell surface (membrane zones rich in 
signaling molecules, thus facilitating T cell activation). The abnormal gene transcription 
profile observed in lupus T cells is also complex, in some aspects it shows the phenotype of 
activated T cells, and in others shares characteristics with anergic cells. Furthermore, the 
abnormally increased expression of the adhesion molecule CD44 on SLE-T cells grants them 
an increased capacity to migrate into inflamed organs. 
Activated SLE T cells provide excessive help to B cells, infiltrate target organs 
causing damage, while failing to produce sufficient interferon-γ and interleukin-2 (IL-2). This 
low IL-2 level may account for the known decreased cytotoxic activity, defective Treg 
function, and decreased activation-induced cell death in SLE patients (7). Moreover, sera of 
patients with lupus contain abnormally high levels of IL-17, that amplifies the inflammatory 
response by recruiting effector cells to target organs, and contributes to the survival and 
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proliferation of B cells and their transformation into antibody-secreting cells. B cell 
overactivity accounts for the abnormal production of a wide spectrum of autoantibodies 
against soluble and cellular constituents, but most commonly against intranuclear antigens 
(ANAs) (9). They form immune complexes that deposit in tissues propagating a chronic 
inflammatory process that destroys organ parenchyma and results in end-stage organ failure. 
It is only a handful of these autoantibodies that have been shown to contribute convincingly to 
disease-related tissue injury, for exaple anti-blood-cell antibodies that activate complement 
and cause cytopenias, and anti-dsDNA antibodies that are thought to contribute to the 
development of nephritis, and crossreact with N-methyl-D-aspartate (NMDA) receptors in the 
brain thereby causing neuropsychological manifestations (7). 
 
1.1. Investigation of the relationship of exocrine gland dysfunction with autoantibodies to 
muscarinic acetylcholine receptor-3 and mental health status parameters in SLE 
overlapping with Sjögren’s syndrome 
 
In SLE, one of the most frequent overlapping autoimmune disease is SS. In this 
syndrome the fundamental symptoms are decreased tear and saliva production, which lead to 
xerostomia and keratoconjuctivitis sicca. The pathogenesis of SS is characterized by the 
chronic inflammation of the exocrine glands, particularly the lachrymal and salivary glands, 
and a wide variety of further immune-mediated organ involvements may develop (10). SS 
often overlaps with other systemic autoimmune diseases including RA or systemic sclerosis, 
but it can also present as a separate entity (primary SS). An associated SS alters the 
immunological phenotype of SLE including the organ manifestations or the 
immunoserological profile (11). 
Similarly to SLE, polyclonal B cell activation dominates the immunological 
alterations of SS, and in the affected secretory tissues focal lymphocytic infiltration can be 
detected. It has previously been observed that the extent of salivary gland tissue damage 
caused by lympocytic infiltration is not proportional to the salivary flow impairment (12). An 
immune-mediated mechanism has been proposeded to impair the glandular function by means 
of autoantibodies which block the functionally dominant muscarinic acetylcholine receptor 
subtype-3 (m3AChR) on acinar cells (13-15). These postsynaptic muscarinic receptors 
modulate the saliva production upon the signals of the autonomic nervous system. The 
11 
 
presence of circulating autoantibodies directed against the m3AChR has previously been 
demonstrated in patients with pSS (16-22), and their binding to muscarinic receptors on 
human salivary gland acinar cells has also been confirmed (23). These anti-m3AChR 
autoantibodies have been hypothesised to block the parasympathetic neurotransmission (15, 
24), thereby serving as an example of how a pathological immunological process can lead to 
organ dysfunction by inhibiting the normal function of the autonomic nervous system.  
Although the role of anti-m3AChR antibodies seems to be established in pSS by 
experimental settings, involving rodent tissues and cultured human salivary glands (24-26), 
formal proof of their functional role in humans is still lacking because a validated 
immunodiagnostic test is still not available. The exact epitope-specificity of anti-m3AChR 
antibodies has also remained yet unidentified, nevertheless several epitopes on the m3AChR 
were proposed as targets of the immune response in SS, specifically on the second and the 
third extracellular loop (20-22, 24, 27). The prevalence and pathogenic role of the various 
anti-m3AChR antibodies have not been systematically examined to date in other systemic 
autoimmune diseases including SLE overlapping with SS. 
Sicca symptoms are common not only in definite SS. A sicca syndrome clinically 
indistinguishable from SS also develops in a considerable proportion of patients with organ-
specific autoimmune diseases, such as primary biliary cirrhosis, multiple sclerosis or gluten-
sensitive enteropathy (28), and in other chronic non-immune-mediated illnesses, such as 
fibromyalgia or chronic fatigue syndrome (29, 30). In the background of the observed 
exocrine insufficiency, the effect of chronic stress and an altered neuro-endocrine homeostasis 
have been presumed, which are modulated by an autonomic nervous system dysfunction. 
Several data raised the concept that chronic stress itself has direct impact on saliva 
production, and it may lead to chronic xerostomia (31-34). It is suggested that the impairment 
of mental health based on chronic stress, depression and the long-standing distress associated 
with systemic autoimmune diseases such as SLE (35, 36) may also negatively influence the 
salivary gland function. No data are available whether mental health alterations may correlate 
with the development of a sicca syndrome in SLE, in addition to the immune-mediated 
mechanisms. 
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1.2. Investigation of the risk of the development of non-thromboembolic organ 
manifestations in systemic lupus erythematosus associated with antiphospholipid syndrome 
 
In SLE, the production of a boundless spectrum of autoantibodies is observed. Some 
of these SLE-related antibodies correlate with the disease activity (e.g. anti-dsDNA), while 
others are markers of specific disease subsets (e.g. anti-Ro/SSA-positivity increases the 
likelihood of subacute cutaneous lupus and congenital lupus including atrioventricular 
conduction block). The formation of antiphospholipid antibodies (APAs) is definitely 
pathogenic (37,38) and their presence defines a specific disease subset. APA positivity itself 
is considered a prothrombotic condition, since these autoantibodies exert widespread effects 
on the coagulation cascade and on the cells involved in haemostasis including endothelial 
cells and thrombocytes. Moreover, APAs facilitate atheroma formation, leading to accelerated 
atherosclerosis (39-41). Knowledge on the associations of autoantibody positivity and organ 
manifestations facilitates a more accurate and timely recognition and a better prevention or 
early treatment of the respective clinical manifestations of SLE. 
The APAs form a heterogeneous group of autoantibodies, that are directed against 
anionic membrane phospholipids and associated proteins. The most common and intensely 
studied members are lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-beta2-
glycoprotein I (aβ2GPI). The latter two antibodies can be present in IgG, IgM and IgA 
isotypes, and the IgG class antibodies in particular are of clinical significance (40, 42, 43). 
The reported prevalence of APAs in SLE varies between 15 and 35% (44-47).  
When the presence of APAs is accompanied by arterial or venous thrombotic events or 
an adverse pregnancy outcome, this clinical condition is called antiphospholipid syndrome 
(APS) (48-50). APS is predominantly associated with SLE of the systemic autoimmune 
diseases, but it can also present as a secondary feature in malignant processes and infections, 
or it may develop as a primary, independent entity. The leading APS-related clinical features 
are the results of hypercoagulability and the specific vaso-occlusive, ischaemic lesions. 
Patients with persistently positive APAs, particularly those who exhibit LA or triple 
autoantibody positivity, are at higher risk for thrombosis, and the risk is also higher in patients 
with arterial thrombosis or those with recurrent thrombosis despite antithrombotic therapy. In 
addition, immune-mediated mechanisms also play role in the development of several 
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manifestations of APS including thrombocytopenia, pregnancy complications and 
neurological symptoms. 
APS complicates SLE by adding a vaso-occlusive factor to the inflammatory 
component that adversely affects the prognosis. APS modifies the clinical picture of SLE also 
in other aspects, for example, cutaneous laesions (e.g. Raynaud’s phenomenon, livedo 
reticularis), Coombs-positive haemolytic anaemia and non-bacterial endocarditis have been 
found to be more common in overlapping disease subsets than in SLE without APS (48, 51). 
APS is also a major predictor of irreversible organ damage and death in patients with SLE 
(51), in part because the development of cardiovascular and cerebrovascular diseases cause a 
substantial morbidity. In summary, the combination of SLE and APS appears to be of greater 
concern than either entity alone. However, little is known about the distinct influence of APS 
on the non-thrombotic disease manifestations of SLE. 
The variable clinical phenotype and heterogenity in the autoantibodies that are 
associated with SLE and APS result in challenges in defining the optimal treatment. The high 
incidence of recurrent thromboembolism that characterizes this condition carries the necessity 
of antithrombotic therapy. While APA positivity itself requires the use of single antiplatelet 
medication, the recommendations for the treatment of APS include long-term anticoagulation. 
In addition, hydroxychloroquine has been shown to reduce the risk of an initial thrombotic 
event in SLE patients with or without APAs, and is frequently used in combination with 
antithrombotic therapy in these patients. When the inflammatory responses predominate the 
clinical picture, immunosuppressive treatments are administered according to the severity of 
the disease. The adverse events in correlation with the treatment eg. bleeding, toxicity or 
infections represent additive risk in the management of SLE + APS patients. 
 
1.3. Investigation of the role of Galectin-1 in the apoptosis of T cells in systemic lupus 
erythematosus 
 
T cell homeostasis and survival plays a crucial role in the loss of peripheral tolearance 
and thus in the development of autoimmune diseases. T cell dysfunction, including the 
malfunction of apoptosis is a major factor in SLE pathophysiology, and dysregulated T cell 
apoptosis in SLE has been reported previously (8). Galectins, a family of beta-galactoside 
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binding lectin-type proteins, are prominent contributors in innate and adaptive immune 
responses. Galectin-1 (Gal-1) has well-defined functions in maintaining immunohomeostasis 
(52, 53), partly via the induction of apoptosis of activated T cells, and growing evidence 
suggests its impact in autoimmune processes. Regarding the T-helper (Th) cell-centered 
autoimmunity and the apototic disturbances of SLE T cells, the possible role of Gal-1 can be 
suggested in the pathogenesis of SLE. 
Gal-1 is present in peripheral lymphoid organs and inflammatory sites, and exerts 
various biological effects as an anti-inflammatory agent and as a suppressor of various T cell 
functions. It has been shown that Gal-1 inhibits cytokine production and induces apoptosis in 
activated Th1 and Th17 cells. This function has been attributed to its secreted form (54). The 
mechanism of Gal-1-triggered cell death has been extensively studied in vitro (55, 56). The 
stimulation of apoptosis requires direct interaction between T cells and the surrounding 
environment (cells or extracellular matrix) (55). The further signaling intracellular pathways 
involve the p56lck and ZAP70 kinases, release of ceramide, decrease of mitochondrial 
membrane potential, and activation of caspases (55, 57, 58). Immunoregulatory function of 
Gal-1 has also been confirmed by in vivo experiments in rodents (56). The differential impact 
of Gal-1 on the T cell subpopulations shifts the immune response from the inflammatory Th1 
to the Th2 direction (59). While inhibiting the cytokine production and triggering apoptosis of 
activated Th1 and Th17 cells, Gal-1 induces cytokine production of Th2 and Treg cells (60). T 
cells are targets of extracellular Gal-1 (exGal-1), nevertheless they produce Gal-1 themselves 
upon activation (61). The function of the de novo expressed Gal-1 (intracellular Gal-1 - inGal-
1) has remained largely elusive. It has been suggested by Blaser et al. that Gal-1 might act as 
an apoptotic factor via autocrine or paracrine mechanisms (61). However, it has not been 
sufficiently proven whether Gal-1 is secreted from the cells or remains intracellularly, and 
possibly contributes to cell death as an intracellular protein. In contrast, recent studies of our 
group have proven that Gal-1 remains intracellularly during T cell activation, and it implies 
that Gal-1 can not perform its physiological activities in the hypothesized autocrine or 
paracrine way. Consequently, we have also proposed that soluble Gal-1 is not an appropriate 
experimental method to study the apoptotic effects of Gal-1, but rather, Gal-1 requires direct 
cell-cell contact to exert its apoptotic effects on T cells. Previous experiments from our 
laboratory have confirmed that exGal-1 deriving from Gal-1 transgenic HeLa tumour cells, 
expressed on the surface of these cells, is a suitable experimental setting for the study of Gal-
1-induced T cell apoptosis (55).  
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The role of Gal-1 in the development and progression of various immune-mediated 
diseases and malignancies has been addressed in some studies. It has been revealed that Gal-1 
expression is diminished at the sites of severe chronic inflammation such as psoriatic skin 
(62). In contrast, the overexpression of Gal-1 is typical in malignant diseases, and this 
promotes tumour immune-escape from anti-tumoural immune surveillance, tumour cell 
dissemination, thereby leading to poor prognosis of cancer patients (52, 53, 104). 
Furthermore, the impact of Gal-1 treatment has recently been shown by in vivo experiments 
including the animal models of autoimmune or inflammatory diseases such as arthritis, colitis, 
hepatitis, nephritis, encephalomyelitis and SLE (63-69). All parameters of experimentally 
induced arthritis, such as incidence, clinical score and paw edema have been found to be 
significantly higher in Gal-1 knockout mice than in wild type animals and Gal-1 therapy has 
been revealed to be efficacious in amelioration of the disease (69). Recombinant Gal-1 
injections suppress the clinical and histological signs of autoimmune encephalomyelitis, a T 
cell mediated disease directed against myelin basic protein, whereby it blocks the sensitization 
of encephalitogenic T cells (68). Regarding the results in experimental SLE, the 
administration of recombinant Gal-1 to SLE-prone mice reduced lymphocyte activation, 
inhibited serum anti-dsDNA IgG antibody production, decreased the incidence of proteinuria, 
and increased survival rate. In addition, aged Gal-1-deficient mice had higher serum levels of 
antibodies against dsDNA. Ex vivo T cells from lupus-mice treated with recombinant Gal-1 
were less efficient in the elicitaion of lipid raft clustering and exhibited less proliferation in 
response to TCR stimulation (65). These therapeutic results suggest the role of 
underexpression of Gal-1 in the pathogenesis of autoimmune disorders including SLE. 
Gal-1 expression in pathological T cells, i.e. activated T lymphocytes from patients 
with autoimmune diseases, has not been specifically investigated so far. There are no 
published investigations available about the expression and immunomodulatory activity of 
Gal-1 in human SLE. Considering the Th1 and Th17 driven autoimmunity and the apototic 
dysregulation of T cells, SLE is suitable to study the function of Gal-1 in pathological 
conditions. 
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2. Objectives 
 
The exact epitope-specificity, the prevalence and the pathogenetic role of the various 
anti-m3AChR antibodies have not yet been studied in SLE overlapping with SS. In this work 
we wished to determine the antigenic epitope of m3AChR which interacts with 
autoantibodies from SLE, RA and pSS patients. Rheumatoid arthritis was included in the 
study as the most common inflammatory rheumatic disease, that may also overlap with SS in 
a significant proportion of the patients. We attempted to develop an appropriate 
immunodiagnostic method for the detection of these anti-m3AChR antibodies, and to 
compare their prevalence in the studied disease groups. Furthermore, we also aimed to assess 
the various disease-specific clinical correlates of the anti-m3AChR autoantibodies in SLE 
patients. With regard to the complex pathogenesis of impaired exocrine gland function, our 
further objective was to address the relative contributions of immunological factors, in 
particular anti-m3AChR antibodies, and mental health status (as assessed with the SF-36 
and the Functional Assessment of Chronic Illness Therapy - FACIT scales) to the elicitation 
of the sicca complex arising in SLE.  
The presence of antiphospholipid antibodies in SLE patients bears the risk of the 
development of certain micro- and macrovascular organ involvements in which acute or 
chronic thrombotic mechanisms are key pathogenetic factors. However, there are no available 
data whether patients with concomitant APS are predisposed to further non-thrombotic SLE-
related morbidities. In this work we set out to define the impacts of APA production alone, 
and an associated APS on the clinical presentation of SLE. Our objective was to compare the 
frequencies of the various non-thrombotic SLE manifestations between the subgroups of 
APA-positive and APA-negative patients, and between the patients with and without 
definitive APS. We aimed to address differences in disease severity and progression between 
the studied patient subsets. Furthermore, we were also searching for correlations of the 
therapeutic requirements in these patient subgroups as this can further modify the clinical 
outcome in addition to the SLE-specific disease manifestations. 
Gal-1 has emerged as an important immunomodulatory factor in autoimmune and 
inflammatory diseases. Although Gal-1 participates in the maintenance of 
immunohomeostasis by regulating T cell functions and survival, its role in the lupus T cell 
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pathology has not yet been explored. In this work, the possible pathogenetic role of Gal-1 was 
studied in SLE. Based on the reported data and the previous results of our study group, we 
hypothesised that the expression of Gal-1 is diminished in SLE T cells compared to healthy 
control cells and, as a consequence, these pathological T cells are less sensitive to the exGal-
1-induced cell death. The aim of our work was to analyse the sensitivity of SLE T cells to 
the exGal-1-mediated apoptotic signal. Furthermore we were searching for a correlation 
between disease activity and the Gal-1 related apoptotic disturbances of SLE T cells. We 
aimed to identify whether different disease activity markers predispose SLE patients to 
decreased T cell apoptosis, thereby contributing to the development of the disease. 
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3. Patients and methods 
 
3.1. Investigation of the relationship of exocrine gland dysfunction with autoantibodies to 
muscarinic acetylcholine receptor-3 and mental health status parameters in systemic lupus 
overlapping with Sjögren’s syndrome 
 
3.1.1. Patients 
In this cross-sectional, case-control study, specific parameters of an overlapping SS 
were studied in 103 SLE patients, and compared with those on 65 patients with RA, 76 
patients with pSS and 50 healthy controls. The mean age of the SLE patients (9 male and 94 
female) was 48 years (25-74 years), that of the RA patients (11 male and 54 female) was 58 
years (22-82 years), and that of the pSS patients (2 male and 74 female) was 56 years (30-76 
years). The disease groups were classified according to the appropriate international criteria: 
the modified 1982 SLE criteria of the American College of Rheumatology (5), the 2010 RA 
criteria of the American College of Rheumatology/European League against Rheumatism 
(70), and the 2002 American-European Consensus Criteria (AECC) for SS (71). 
The presence of sicca complex was evalualed in the SLE and RA patients. 
Corresponding to the AECC for SS, objective exocrine deficiency was evaluated by means of 
the Schirmer test and the measurement of unstimulated whole saliva production, while 
subjective sicca complaints were regarded as present if at least one of the three questions 
included in these criteria was answered positively. Sicca complex was defined when at least 
one positive objective test on at least two separate occasions was associated with subjective 
sicca symptoms of both the eye and the mouth. Labial salivary gland biopsy was not 
performed in several patients for ethical reasons, this limited the determination of the 
presence of secondary SS (sSS) as classified by the AECC.  
Numerous disease-specific clinical and immunoserological data were collected on the 
SLE and RA patients to assess the correlates of sicca complex. Selected clinical parameters, 
including the immunoserological profile of SLE and RA, are presented in Table 1.  
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SLE (n=103) % RA (n=65) % 
polyarthritis 89.2 rheumatoid nodules 12.5 
photosensitivity 70.6 pulmonary fibrosis 4.7 
nephritis 30.4 RF 84.4 
serositis 28.4 anti-MCV 77.9 
nervous system 21.6 anti-SSA 9.5 
lymphopenia 51,5 anti-SSB 7.1 
anti-dsDNA 74.2   
anti-SSA 50.5   
anti-SSB 38.6   
low C3, C4 67.6   
 
Table 1. Characteristic clinical and laboratory variables of SLE (n=103) and RA (n=65). 
anti-dsDNA: antibody to double-stranded DNA; C3, C4: complement-3 or -4; RF: 
Rheumatoid factor; anti-MCV: anti-mutant citrullinated vimentin 
 
The patients were on usual immunosuppressive therapies, the most frequently 
administered therapies for SLE being low dose corticosteroid, chloroquine, azathioprine, 
cyclopsosphamide or mycophenolate mofetil, and for RA low dose corticosteroid, 
methotrexate, leflunomide, TNFα inhibitor or anti-CD20 biologic agents. Most of the pSS 
patients received only symptomatic treatment, but a significant minority was also treated with 
immunosuppressive therapy, most commonly corticosteroid, chloroquine, or azathioprine. 
The impact of the immunosuppressive drugs as well as those with anticholinergic effects, 
specifically antihistaminic, antidepressant, antipsychotic, antispasmodic, antiemetic and 
antiepileptic drugs, on the exocrine function was assessed.  
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3.1.2. Organ involvements 
The diagnosis of the lupus-related organ involvements were established on standard 
clinical methods, radiological and histological findings. The manifestations involving the 
heart, the lungs, the kidneys and the central nervous system were considered as major organ 
manifestations, as these have a profound impact on the outcome of the disease. Only the 
manifestations directly attributable to the disease were considered lupus-related, and other 
causes of organ damage or any other pathological condition e.g. drug or infection-related 
symptoms were excluded. The definitions of selected organ manifestations were as follows: 
Pulmonary involvement: specific signs of parenchymal lung disease, including interstitial 
pneumonitis, chronic fibrosing alveolitis (pulmonary fibrosis) or acute alveolitis demonstrated 
by radiological examination. 
Nephritis: biopsy-proven lupus glomerulonephritis exhibiting a characteristic histological 
picture (class I-V. lupus nephritis) or, if a biopsy was not performed, the presence of 
proteinuria >/= 0.5 g/die and/or microscopic hematuria and/or cylindruria not explained by 
any condition other than active SLE. 
Skin vasculitis: clinical presence of cutaneous vasculitis including periungual vasculitis, 
digital vasculitis, nodular vasculitis, livedo vasculitis, urticaria vasculitis, purpura or crural 
ulcers, in selected cases verified by histological examination. 
Neuropathy: cranial and peripheral inflammatory neuropathies. 
Organic brain syndrome: diffuse brain tissue damage with acute or chronic psycho-organic 
syndrome (acute confusional state or accelerated cognitive dysfunction). 
Overlapping Sjögren's syndrome: presence of objective and subjective sicca symptoms 
affecting the eyes and/or the mouth, with decreased tear and/or saliva production, meeting the 
AECC for Sjögren’s syndrome (71). 
3.1.3. Laboratory tests 
The tests were performed at the Department of Laboratory Medicine of our University 
by means of routine diagnostic methods (ELISA, nephelometry, LA-sensitive coagulation 
tests, etc.). The evaluated laboratory features of SLE included leucopenia (WBC <4.0 G/l), 
lymphopenia (Ly count <1.5 G/l), haemolytic and non-haemolytic anaemia (haematocrit 
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<35%), and thrombopenia (platelet count <100 G/l). We also studied the immunoserological 
profile of the patients: anti-dsDNA, ANA, anti-SSA, anti-SSB, anti-RNP, anti-Sm, LA, aCL, 
aβ2GPI and hypocomplementaemia (C3 and C4) were assessed.  
3.1.4. Antigen preparation 
The computer software “Peptide Companion” Version 1.231 (Coshisoft/PeptiSearch) 
was used to identify immunodominant epitopes of the human m3AChR, and  peptide aa184-
227 (AGSE) from the second extracellular loop of the receptor; peptide aa506-521 (YNIP) 
from the third extracellular loop; and peptide aa360-377 (TRIC) from the third intracellular 
loop have been selected as antigens. AGSE peptide is localised in the ligand binding region of 
the m3AChR. 
Then we aimed to test whether the modification of m3AChR pepides could amplify 
the antigenicity and enhance the detection of the autoantibodies specific to the respective 
peptides with ELISA. Various forms of these antigens were prepared: First, short linear 
peptides were synthesised with solid-phase peptide synthesis as described in an earlier 
publication of our group (16). Afterwards, we constructed a recombinant fusion protein 
containing the peptides AGSE and YNIP fused with glutathion-S-transferase (GST). With this 
modification of the protein microenvironment, we expected to facilitate the assumption of an 
appropriate physiological conformation of the studied peptides (72). Briefly, peptide-coding 
DNA sequences were assembled from synthetic oligonucleotides, and cloned into expression 
vectors in fusion with GST; the fusion product was expressed in Escherichia coli and purified 
by affinity chromatography (the details are to be seen in reference 16). AGSE peptide was 
predicted to possess the strongest antigenicity, so finally this epitope was also prepared in 
multiple conjugation to bovine serum albumin (BSA), aiming to boost the sensitivity of the 
assay. The results of the ELISA studies using the described three different forms of the 
antigens were compared. 
3.1.5. ELISA techniques 
The specific antigens were coated on microtitre plates as follows: 1 µg/ml of the 
AGSE, 2 µg/ml of the YNIP and TRIC synthetic peptides, and 10 µg/ml of the GST-fusion 
products and the BSA-conjugated antigen. The prepared plates were incubated overnight at 4 
°C, then patient sera were added at a dilution of 1:200 in PBS-TWEEN followed by 
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peroxidase-labelled anti-human IgG (1:2500 in PBS-TWEEN; Sigma-Aldrich Hungary, 
Budapest). After adding ortho-phenylene diamine to the samples, optical density (OD) was 
read at 492 and 620 nm. For the GST- or BSA-conjugated proteins, the specific corrected OD 
characterizing the m3AChR-specific epitope within an individual sample was calculated by 
subtracting the OD for the GST or BSA protein from that for the GST-m3AChR peptide 
fusion protein or BSA-AGSE conjugate. Appropriate numbers of negative controls were used 
for every microtitre plate, and measurements were made in duplicate. As the absolute OD 
values for the negative controls varied from plate to plate, the OD values of the patients’ 
samples were normalized to the mean of the controls for every plate by dividing the OD of the 
test sample by the cut-off (mean + 2SD of the negative control OD values). The resulting 
relative OD values were used for the calculations.  
3.1.6. Mental health status assessments 
By means of specific questionnaires we have assessed the physical and mental health 
of the patients. The FACIT fatigue scale and the SF-36 survey were applied (73, 74). The 
FACIT fatigue scale is a short, 13-item query that shows the patient’s level of fatigue during 
the usual daily activities over the past week (73). The SF-36 questionnaire is set up of 36 
questions which represent multiple indicators of physical and mental health, including 
behavioural function and dysfunction, distress and well-being, objective reports and 
subjective ratings, and both favourable and unfavourable self-evaluations of the general health 
status (74).  
3.1.7. Statistical methods 
The statistical analyses were performed with SPSS 15.0 software. Levels of p < 0.05 
were taken as statistically significant. The demographic, clinical and immunoserological 
parameters, the levels of anti-m3AChR antibodies specific to the various antigens and the SF-
36 and FACIT test results were compared between the SLE and RA patients with or without 
sicca complex by means of the Student t-test or Fisher’s exact test as appropriate, depending 
on whether continuous or categorical variables were tested. To test whether the administration 
of certain immunosuppressive drugs or those with anticholinergic effects had an effect on the 
exocrine function, the chi2 test was applied. The differences of mean autoantibody 
concentrations between the studied groups were assessed with analysis of variance with 
Bonferroni’s correction as a post hoc test. The occurrences of positivities to the various 
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antigenic epitopes were compared between the different patient and control groups with the 
chi2 test.  
 
3.2. Investigation of the risk of the development of non-thromboembolic organ 
manifestations in systemic lupus erythematosus associated with antiphospholipid syndrome 
 
3.2.1. Patients 
In this retrospective cohort study on an unselected group of consecutive SLE patients, 
we have assessed the risk of the development of non-thromboembolic disease manifestations 
of SLE with relation to the presence of APAs or APS. Data of 224 adult patients (age >18 
years) were evaluated. All of the enrolled patients fulfilled the updated ACR criteria for the 
classification of SLE (5). The mean age of the patients at the time of inclusion was 49 (20-92) 
years, while the average length of time since the diagnosis was established was 13 (0-49) 
years. The proportion of female patients was 91% (n= 204) 
The presence of APS was established following the Sydney criteria (75). The 
diagnosis of APS required APA positivity coexisting with documented obstetric and/or 
thrombotic complications. APA-s were considered positive when at least two laboratory tests 
12 weeks apart were positive for LA or aCL or aβ2GPI IgG and/or IgM.  
Selected clinical and laboratory parameters of SLE and APS were compared between 
patients with or without APA positivity. In addition, data of the patients in whom SLE was 
associated with APS were also evaluated in comparison with those of the SLE patients 
without APS. We studied the following three categories: organ involvement, laboratory 
features and immunosuppressive therapy. Thirty-one different organ involvements of SLE 
were included in the analysis. The definition of selected manifestations is detailed in Section 
3.1.2. Laboratory measurements were performed with the methods described in 3.1.3. 
3.2.2. Immunosuppressive therapy 
The patients were treated according to the current international guidelines. Milder (e.g. 
chloroquine) or more potent immunomodulatory agents (e.g. cyclophosphamide) were 
administered depending on the severity of the disease. Medication with oral or i.v. 
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corticosteroid, chloroquine, azathioprine, methotrexate, cyclosporine or i.v. 
cyclophosphamide was recorded. The number of patients taking mycophenolate mofetil or 
rituximab was small, and therefore statistical analyses were not feasible. 
3.2.3. Statistical methods 
In the studied patient subgroups (SLE +/- APA, SLE +/-APS) the differences between 
the occurrence of the various organ manifestations, the immunoserological parameters and the 
specific treatment modes were calculated with the chi2 test. Levels of p < 0.05 were taken as 
statistically significant.  
 
3.3. Investigation of the role of Galectin-1 in the apoptosis of T cells in systemic lupus 
erythematosus 
 
3.3.1. Patients 
We performed a prospective, controlled study, involving 18 adult SLE patients (age 
>18 years). All of the enrolled subjects fulfilled the updated ACR criteria for the classification 
of SLE (5). All patients were female, their mean age at the time of inclusion was 42 (19-71) 
years, while the average length of time since the diagnosis was established was 4 (0,2-16) 
years. The control group consisted of 20 age- and sex- matched healthy volunteers. 
Disease activity was evaluated with the SLE Disease Activity Index 2000 (SLEDAI-
2K) (76), anti-dsDNA antibody levels, and erythrocyte sedimentation rate (ESR). The 
inclusion criteria for the patients were set at SLEDAI-2K score of 7 or above („active SLE” 
group). Newly diagnosed patients without SLE specific medication were preferred for 
enrollment (11/18). Moreover, patients with relapsing disease on low dose 
immunomodulatory drugs - methylprednisolone </= 12 mg/day (7/18), azathioprine <150 
mg/day (2/18) and methotrexate 10 mg/week (2/18) - were also included.  
The first blood samples were taken at the time of active SLE before starting or 
intensifying an immunosuppressive therapy. The second blood samples were taken when the 
enrolled patients’ disease has become quiescent after treatment (“inactive SLE” group - 
SLEDAI-2K < 7 or decrease in SLEDAI-2K >/= 7). Ten SLE patients were eligible for the 
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second measurements. Treatments stably maintained for at least two months at the second 
blood sampling included low-dose (< 20 mg prednisolone) corticosteroid, chloroquine, 
azathioprine, methotrexate, cyclosporine or epratuzumab. Selected characteriscics of the 
patients were also recorded, including the immunological and haematological laboratory 
findings at the time of enrollment and the subsequently applied therapies. The upper limit of 
cytopenias were set as follows: anaemia - haematocrit < 35%, leucopenia - WBC < 4.0 G/l, 
lymphopenia - Ly count < 1.5 G/l, thrombopenia - platelet count < 100 G/l (Table 2).  
 
Autoantibodies % Cytopenia % Therapies % 
ANA 63,6 Anaemia 63,6 Oral steroid 95,5 
anti-dsDNA 90,9 Coombs positivity 18,2 I.v. steroid 68,2 
anti-SSA 36,4 Leucopenia 50 Azathioprine 63,6 
anti-SSB 22,7 Lymphopenia 50 Chloroquine 59,1 
anti-Sm 27,3 Thrombopenia 13,6 Cyclophosphamide 36,4 
anti-RNP 27,3   Methotrexate 31,8 
anti-CL 13,6   Mycophenolate 9,1 
anti-ß2GPI 9,1   Cyclosporine A 4,5 
LA 9,1   Epratuzumab 9,1 
low C3 63,6     
low C4 40,9     
 
Table 2. Prevalence of autoantibodies, cytopenias and therapies applied ever during the 
disease course in the cohort of SLE patients of section 3.3.1 (n=18). ANA: anti-nuclear 
antibodies, anti-dsDNA: anti-double stranded DNA, anti-SSA: anti-Sjögren’s syndrome A, 
anti-SSB: anti-Sjögren’s syndrome B, anti-Sm: anti-Smith, anti-RNP: anti-ribonucleoprotein, 
aCL: anti-cardiolipin,  anti- ß2GPI: anti-beta2glycoprotein I, LA: lupus anticoagulant, C3: 
complement 3, C4: complement4, i.v.: intravenous. 
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3.3.2. Cells 
Blood samples from SLE patients and healthy donors were separated using Ficoll (GE 
Healthcare) gradient centrifugation. Activated T cells were prepared as follows: peripheral 
blood mononuclear cells (PBMC) were stimulated with 5 µg/ml Phytohaemagglutinin (PHA-
M, Sigma-Aldrich) and were cultured for 72 hours at 37 °C in RPMI-1640 medium (Gibco) 
supplemented with 10% FCS, 2 mM L-glutamine, 100 IU penicillin and 100 µg/ml 
streptomycin. 
The studied HeLa human cervix adenocarcinoma cells were transfected as described 
previously (55). Mock transfected (HeLamock) or Gal-1 transgenic (HeLaGal) human cervix 
adenocarcinoma cells were cultured in MEM (Gibco, Invitrogen) supplemented with 100 IU 
penicillin, 100 µg/ml streptomycin, 2mM L-glutamine and 10% FCS.  
3.3.3. Gal-1 induced T cell apoptosis in co-culture 
Apoptosis induced by cell-derived Gal-1 was assessed as previously described by our 
group (55) To detect the Gal-1 induced T cell death, we applied co-cultures of HeLa cells and 
the SLE patients’ T cells. Normally, T cells die when co-cultured with Gal-1 expressing 
(HeLaGal) but survive with Gal-1 non-expressing (HeLamock) tumour cells. 
HeLamock (control) or HeLaGal cells (effector cells, 5×103 cells/sample) were plated on 
cover slips. The nuclear DNA of activated target T cells (2×105 cells/sample) was labelled 
with Hoechst 33342 fluorescent dye (100 ng/ml for 30 min at 37 °C) and co-cultured with 
both HeLa cell lines for 16 hours. Then T cells were labelled for phosphatidyl-serine exposure 
on the outer cell membrane, which is an early apoptotic signal of the cells, using fluorescent 
staining by Annexin V-Alexa Fluor 488 (Invitrogen) for 30 min and mounted with 
Fluoromount-G. Finally, the samples were analyzed with Carl Zeiss (Axioskop 2Mot) 
fluorescence microscope using AxioCam camera, AxioVision 3.1 software and 20 × objective 
magnifications. The contrasts of the images were adjusted using Adobe Photoshop CS4 
Extended.  
The degree of apoptosis was determined by counting at least 100 cells/ sample and 
was calculated as follows: % of apoptotic cells = (Annexin V positive cells/ total cell number) 
× 100. The exGal-1 induced T cell apoptosis was quantified as relative apoptotic ratio (RAR), 
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that represents the difference of the apoptotic cell ratios between the co-cultures applying 
HeLaGal and HeLamock cells.  
3.3.4. Statistical methods 
Data had normal distribution, therefore, the Student t-test was used for the comparison 
of RAR values between both SLE patient groups and the controls and also between the two 
SLE groups. Correlations between Gal-1 mRNA expression levels and RAR values with each 
other, and with disease activity parameters were assessed with Pearson’s correlation test, or 
Spearman’s signed rank test for the ESR. Data are presented as mean ± SD, and p < 0.05 
values were regarded as statistically significant. 
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4. Results 
 
4.1. Investigation of the relationship of exocrine gland dysfunction with autoantibodies to 
muscarinic acetylcholine receptor-3 and mental health status parameters in SLE 
overlapping Sjögren’s syndrome 
 
4.1.1. Anti-m3AChR detection 
Figure 1 shows the mean levels of anti-m3AChR antibodies depending on the method 
of antigen preparation and epitope-specificity in the SLE, RA and pSS patients and the 
healthy controls. Significantly higher mean autoantibody levels were detected in both the SLE 
and the pSS patients than in the controls using the single peptide corresponding to the second 
(AGSE) and the third (YNIP) extracellular loops, while the RA patients exhibited only a 
borderline significant difference versus controls (p=0.067). This method applying short 
peptide sequences failed to make further distinctions between the SLE, pSS, and RA patients. 
The studies with the AGSE epitope in fusion with GST displayed significantly lower mean 
antibody levels in RA as compared with the other two patient groups. When the BSA 
conjugate was presented in ELISA, the mean autoantibody levels to this antigen were higher 
in all three diseases than in the controls, thus this modification failed to identify antibodies 
with sufficient group-discriminative power. The TRIC peptide, which is located in the 
intracellular portion of the m3AChR cannot be regarded antigenic in these diseases, since it 
reacted with only a small proportion of the sera.  
The prevalence of the studied antibodies is demonstrated in Figure 2. Autoantibodies 
to the short synthetic peptides of AGSE and YNIP were detected at significantly higher 
frequencies in all three disease groups than in the controls. In addition, the presentation of 
GST-fusion forms also discriminated the patient groups: the prevalences of GST-AGSE and 
GST-YNIP were elevated in both SLE and pSS as compared with RA, furthermore antibodies 
to GST-YNIP also revealed differences between SLE and pSS patients, as these antibodies 
occurred at significantly higher frequency in pSS than in SLE, though in SLE it was still 
significantly more prevalent than in RA or in the controls.  
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Figure. 1. Mean relative OD values of anti-m3AChR antibodies measured with ELISA.  
GAGSE: GST-AGSE fusion peptide, GYNIP: GST-YNIP fusion peptide, BAGSE: BSA-
AGSE multiple-conjugated peptide; SS: primary Sjögren’s syndrome; SLE: Systemic lupus 
erythematosus; RA: Rheumatoid arthritis,* p<0,05 vs control; # p<0,05 vs RA  
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Figure 2. The prevalences of anti-m3AChR antibody-positivities in the three diseases and the 
controls. For the abbreviations, see the legends of Figure 1. * p<0,05 vs control; # p<0,05 vs 
RA; x p<0,05 vs SLE  
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After these assessments it became evident that short peptide sequences detect anti-
m3AChR with relatively high specificity but low sensitivity, whereas fusion with GST is able 
to preserve the specificity and enhance the sensitivity of detection of anti-GST-YNIP. 
Multiple epitope conjugation to BSA does not improve the sensitivity of the ELISA technique 
(Table 3). 
 
  Sensitivity Specificity 
AGSE 41,2% 92,0% 
YNIP 41,2% 94,0% 
TRIC 17,6% 92,0% 
GAGSE 75,6% 58,1% 
GYNIP 86,5% 100,0% 
BAGSE 34,7% 98,2% 
 
Table 3. Sensitivity and specificity of the tests for the detection of anti-m3AChR antibodies. 
For the abbreviations, see the legends of Figure 1. 
 
4.1.2. Correlations of the sicca complex with clinical, immunoserological and mental health 
parameters 
The clinical presentation of SS overlapping with SLE was analysed, and compared 
with that in RA. Sicca symptoms were common in both patient groups: sicca complex was 
established in 27 (26.2%) SLE and 14 (21.5%) RA patients. We aimed to identify clinical, 
immunological and psychosomatic correlates of the sicca complex. We studied the sicca and 
non-sicca patients regarding age, disease duration, disease-specific organ involvements, 
medication, immunoserology, mental health status parameters, as well as the anti-muscarinic 
receptor antibody positivity and epitope specificity.  
As described before, anti-m3AChR antibodies specific to the second or the third 
extracellular loops and to the third intracellular loop occurred in both SLE and RA patients, 
however the prevalence (Table 4) and the mean levels of these autoantibodies were not 
statistically different between the patient subgroups of SLE or RA with or without sicca 
complex (mean level data not shown). 
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 SLE + sicca SLE - sicca RA + sicca RA - sicca 
AGSE 43,7% 48,6% 22,2% 25,6% 
YNIP 43,7% 45,9% 33,3% 25,6% 
TRIC 37,5% 21,6% 11,1% 16,3% 
GAGSE 81,2% 64,4% 18,2% 37,8% 
GYNIP 17,6% 48,0% 55,5% 29,0% 
BAGSE 25,9% 44,7% 28,6% 27,4% 
 
Table 4. Prevalence of the anti-m3AChR autoantibodies in the subgroups of SLE and RA with 
or without sicca complex. For the abbreviations, see the legends of Figure 1. 
 
Decreased saliva production correlated with increasing age in both SLE and RA 
patients as expected. Furthermore, this study revealed that those SLE patients who had sicca 
complex developed organic brain syndrome, stroke and anti-SSA antibody positivity more 
frequently, whereas they presented with nephritis and lymphopenia more rarely than the non-
sicca SLE patients, all with borderline significance (Table 5). Regarding the mental status, the 
FACIT fatigue scale did not reveal differences between the subgroups of sicca and non-sicca 
SLE patients. However, in the SF-36 survey, sicca SLE patients proved to have significantly 
impaired mental health parameters, specifically, in the “role-physical”, the vitality, the social 
function, the mental health domain, and the mental composite score as compared with the 
SLE patients without sicca syndrome (Table 5). In contrast, the RA patients showed no 
clinical or immunological correlates other than increasing age that could discriminate between 
those with or without sicca complex. Interestingly, none of the parameters that characterize 
the fatigue (FACIT) or the quality of life (SF-36) were found to correlate with the presence of 
sicca syndrome in RA. Finally, the impact of the immunosuppressive drugs as well as those 
with anticholinergic effects was assessed. Five SLE patients were on anticholinergic therapy. 
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The treatment with none of the studied medications showed a correlation with the presence of 
sicca complex (data not shown).  
 
selected SLE-related 
parameters 
non-sicca (%) sicca (%) p 
organic brain syndrome 1,3 11,1 0,056 
stroke 0 7,4 0,068 
anti-SSA 45,9 62,9 0,098 
nephritis 34,6 18,5 0,091 
lymphopenia 57,3 37 0,056 
SF-36 mean values p 
role-physical  39,33 35,05  0,081 
vitality  46,71 41,70  0,005 
social functioning  42,68 38,04  0,041 
mental health  42,12 36,82  0,048 
mental composite score  44,01 38,52  0,035 
 
Table 5. Differences in the occurrence of selected clinical or laboratory paremeters and SF-
36 items of the sicca and non-sicca SLE patients. Significant differences are written in bold. 
Higher SF-36 mean values represent better health status. 
 
4.2. Investigation of the risk of the development of non-thromboembolic organ 
manifestations in systemic lupus erythematosus associated with antiphospholipid syndrome 
 
4.2.1. Characteristics of the overall cohort 
The most common disease manifestations, immunoserological variables and 
immunosuppressive mediacations are presented in Table 6.  
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  %  % 
Arthritis 89.3 ANA 87.1 
Photosensitivity 65.2 anti-dsDNA 76.3 
Non-haemolytic anaemia 56.3 anti-SSA 46.0 
Raynaud’s phenomenon 54.9 anti-SSB 33.9 
Leucopenia 54.0 anti-Sm 21.4 
Lymphopenia 46.0 anti-RNP 16.1 
Other skin manifestations 32.1 anti-CL 35.3 
Lymphadenomegaly 31.3 anti-ß2GPI 23.2 
Pleuritis 30.4 LA 24.6 
Pericarditis 24.1 low C3 62.9 
Butterfly erythema 20.5 low C4 46.4 
Venous thromboembolism 19.2 oral corticosteroid 90.2 
Skin vasculitis 18.8 i.v. corticosteroid 37.5 
Thrombopenia 17.9 chloroquin 62.9 
Overlap Sjögren's syndrome 17.9 azathioprin 34.4 
Haemolytic anaemia 14.7 i.v. cyclophosphamide 25.9 
Oral ulceration 10.3 methotrexate 21.0 
Repeated spontaneous abortion 5.2* cyclosporin A 9.8 
Nephritis 35.3   
Pulmonary involvement 8.9   
Organic brain syndrome 7.1   
Stroke 4.5   
Myocarditis 3.6   
Convulsion 3.6   
Psychosis 2.7   
Endocarditis 1.3   
 
Table 6. Prevalences of the most common and the major clinical manifestations, the 
immunoserological abnormalities and the immunosuppressive therapies in the studied SLE 
patients. SLE: systemic lupus erythematosus, aCL: anti-cardiolipin,  anti-ß2GPI: anti-beta2-
glycoprotein I, LA: lupus anticoagulant, ANA: anti-nuclear antibodies, anti-dsDNA: anti-
double stranded DNA, anti-SSA: anti-Sjögren’s syndrome A, anti-SSB: anti-Sjögren’s 
syndrome B, i.v.: intravenous, Numbers indicate percentages. * in female patients. The major 
manifastations are written in bold. 
 
The APS-related clinical manifestations were venous thromboembolism (39 patients), 
stroke (8 patients), and repeated spontaneous abortion or intrauterine death (9 patients). The 
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frequency of the distinct APAs ranged between 20 and 33%. One hundred and five (47%) 
patients were found to produce at least one type of APA according to the Sidney criteria, and 
52 of these APA-positive patients (23% of the total) fulfilled the criteria for APS (Figure 3).  
The frequency of APS among our patients is in accord with the literature findings that 15-30% 
of SLE cases are associated with APS (48, 49, 77). 
 
Figure 3. Proportions of APA-positive, APA-negative and APS patient subgroups. APA: 
antiphospholipid antibody, APS: antiphospholipid syndrome. 
 
4.2.2. The impact of antiphospholipid antibody positivity 
Several clinical distinctions were identified between the APA-positive (n=105) and 
negative patients (n=119) (Table 7).  
 
 
Mean number 
of total organ 
involvements 
Endocarditis 
(%) 
Venous 
thrombo-
embolism 
(%) 
Haemolytic 
anaemia 
(%) 
Thrombopenia 
(%) 
APA+ 7.6 2.8 29.5 21.9 25.7 
APA- 6.8 0 10.1 8.4 10.9 
p <0.05 0.101 0.000 0.007 0.005 
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Table 7. Clinical differences between the APA+ and the APA- SLE patients.  
APA: antiphospholipid antibody, SLE: systemic lupus erythematosus. 
 
The APA-positive patients exhibited significantly higher morbidity than the APA-
negative patients, as indicated by the significantly higher total number of organ involvements 
detected during the course of the disease. In addition to the expected complication of venous 
thromboembolism, haemolytic anaemia, thrombopenia and endocarditis were also observed 
nearly three times more often in the APA-positive patients than in those without APAs. 
Endocarditis occurred exclusively in APA-positive patients, supporting the role of APA 
positivity as a risk factor in the development of non-bacterial endocarditis. 
4.2.3. The clinical presentation of SLE with secondary antiphospholipid syndrome 
Significant clinical differences were detected in the disease course of the patients in 
whom SLE was accompanied by secondary APS in comparison with the APS-negative SLE 
subgroup (Table 8).  
 
 
SLE + APS SLE withoutAPS 
Stroke 15.4% 1.2% 
Venous thromboembolism 75.0% 2.3% 
Repeated spontaneous abortion 17.3% 1.25% 
Pleuritis 40.4%  24.3 % 
Nephritis 53.9% 29.4% 
Myocarditis 7.7% 2.3% 
Pulmonary involvement 17.3% 6.4% 
Organic brain syndrome 13.5% 5.2% 
Thrombopenia 26.9% 17.8% 
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Total number of organ 
involvements per patient 
8.1 6.9 
Total number of major organ 
involvements per patient 
1.2 0.5 
i.v. corticosteroid 56% 32% 
azathioprine 52% 29% 
cyclophosphamide 39% 22% 
 
Table 8. Differences in the frequency of selected organ involvements and in the therapeutical 
requirements between the SLE + APS and SLE without APS patients (p<0.05).  
APS: antiphospholipid syndrome, SLE: systemic lupus erythematosus, i.v: intravenous. 
 
Corresponding to the definition of APS, venous thromboembolism, stroke and 
spontaneous abortion were more common in this patient subgroup than in the absence of APS. 
Moreover, our results revealed that a significantly higher proportion of the APS cases 
developed nephritis, interstitial pulmonary involvement, pleuritis, myocarditis, organic brain 
syndrome or thrombopenia than in the non-APS group (Table 8). Renal involvement is known 
to be crucial in determining the outcome of the disease, thus it is noteworthy that lupus 
glomerulonephritis was present in more than half of the SLE + APS cases. 
APS patients also proved to develop a higher total number of organ involvements 
compared with the APA-negative patients (8.1 vs 6.9; p <0.05), similarly to that seen in the 
cases with APA-positivity alone. In addition, major SLE manifestations were diagnosed 
significantly more frequently in patients with APS than in patients without APS (average 
numbers per patient: 1.2 vs 0.5; p < 0.05). Stroke, as a thrombotic event typically present in 
APS, was excluded from the major organ involvements in this comparison. However, APA 
positivity alone did not lead to an increased incidence of major SLE manifestations.  
The assessments of the therapeutic medications also confirmed the more severe 
disease course in APS, since it implies the need for more aggressive therapy. When SLE was 
complicated by APS, the patients required i.v. corticosteroid, cyclophosphamide, or 
azathioprine significantly more often than in the absence of APS (Table 8) 
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4.3. Investigation of the role of Galectin-1 in the apoptosis of T cells in systemic lupus 
erythematosus 
 
4.3.1. SLE disease activity 
 Disease activity was evaluated with the SLEDAI-2K index, anti-DNA antibody levels, 
and ESR at the time of enrollment and after therapy. The characteristics of disease activity in 
the patient subgroups of active and inactive SLE are shown in Table 9.  
 
Patient No. SLEDAI 1. SLEDAI 2. 
anti-
dsDNA 1. 
anti-
dsDNA 2. 
ESR 1. ESR 2. 
SLE1 14 0 200 17 63 12 
SLE2 17 2 220 30 41 16 
SLE3 23 6 151 39 76 31 
SLE4 18 8 220 84 54 39 
SLE5 18 2 220 75 60 7 
SLE6 17 10 65 57 70 6 
SLE7 7 2 130 140 63 NA 
SLE8 15 4 220 51 95 11 
SLE9 26 2 220 27 39 11 
SLE10 12 0 12 5 93 70 
SLE11 11  220  54  
SLE12 9  74  120  
SLE13 12  220  12  
SLE14 7  13  37  
SLE15 28  220  58  
SLE16 12  81  26  
SLE17 12  220  53  
SLE18 7  67  73  
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Table 9. Parameters of disease activity in SLE patients before (1. – active, n=18) and after (2. 
– inactive, n=10) therapy.  
SLE: systemic lupus erythematosus, SLEDAI: SLE disease activity index 2000, anti-dsDNA: 
anti-double stranded DNA, ESR: erythrocyte sedimentation rate, NA: not available. 
 
4.3.2. Apoptotic response of activated SLE T cells to extracellular Gal-1 
Recent studies of our group confirmed that the presence of endogenous, inGal-1 in the 
target T cells has an impact on the apoptotic response induced by exGal-1. T cells expressing 
Gal-1 upon activation display higher sensitivity to the exGal-1 induced apoptosis. 
In the present work the apoptotic response of activated SLE T cells to exGal-1 was 
measured in co-culture experiments, in which exGal-1 was delivered by direct cell-cell 
contact between activated T cells and Gal-1 producing HeLa tumour cells. In active phase of 
the disease, SLE T cells displayed nearly zero apoptotic response to the effects of exGal-1, 
while, as expected, the healthy controls exhibited an apoptotic reaction in many T cells, 
similarly to the previous observations of our group. The difference was highly significant 
(mean RAR of -0,19 ± 7,26 vs 11,06 ± 10,19; p=0,0004). The susceptibility to apoptosis 
increased after the disease has become quiescent, as reflected by the significant mean increase 
of RAR from -0,19 ± 7,26 to 6,59 ± 7,85 (p=0,029). Results were compared between healthy 
controls and inactive SLE patients as well, and no significant difference could be detected 
between the two groups (mean RAR of 11,06 ± 10,19 vs. 6,59 ± 7,85; p=0,26) (Figure 4). 
Representative images of T cell apoptosis in co-culture with Gal-1 producing HeLa cells from 
a patient with active SLE and from a healthy control is presented in Figure 5. 
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Figure 4. Apoptotic response of activated SLE T cells to extracellular Gal-1in the active and 
inactive phase of the disease, compared to healthy controls 
HC: healthy control, n= 20; Active SLE, n= 18; Inactive (treated) SLE, n=10; RAR: relative 
apoptotic ratio; *** p < 0.001; * p < 0.05; n.s.: not significant 
 
 1.               2.                                  1.                        2. 
Figure 5. T cell apoptosis after 16 hours of co-culture with Gal-1 producing HeLa cells in a 
patient with active SLE (1.) and in a control (2). Image under fluorescecnce microscope, 
edited by Adobe Photoshop. T cell nuclear DNA was stained with blue fluorescent Hoechst 
33342 dye, and phosphatidyl-serine exposure on the outer cell membrane of apoptotic T cells 
was revealed by means of staining with green fluorescent Annexin V-Alexa Fluor 488 dye. T 
cells with Annexin V-positive cell membrane display apoptosis.  
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In parallel with the co-culture experiments, our group has also measured the 
expression of inGal-1 by means of quantitative real time PCR in SLE and control activated T 
cells. Gal-1 expression represented by Gal-1 mRNA level was diminished significantly in 
active SLE patients compared to the controls. After treatment, SLE T cells produced 
significantly more Gal-1 mRNA, reaching a similar level to that of healthy controls (data not 
shown).  
We have analyzed the correlation between the inGal-1 expression and the apoptotic 
sensitivity of the same samples of activated T cells of the individual patients and controls. We 
could not determine direct correlation between the studied parameters neither in SLE nor in 
healthy T cells (p > 0,05). We were also searching for correlations between both Gal-1 
mRNA expression levels and RAR values with disease activity measures in lupus patients. 
The individual values of the Gal-1 mRNA levels and also the RAR did not correlate with the 
parameters of disease activity such as SLEDAI-2K, anti-dsDNA antibodies or ESR (p > 0,05). 
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5. Discussion 
 
5.1. Investigation of the relationship of exocrine gland dysfunction with autoantibodies to 
muscarinic acetylcholine receptor-3 and mental health status parameters in systemic lupus 
overlapping with Sjögren’s syndrome 
 
This work has revealed two distinct neuroimmune alterations that may contribute to 
the complex pathophysiology of exocrine gland dysfunction in SLE overlapping with SS: 
autoantibody production that directly targets m3AChR, the specific autonomic 
neurotransmitter receptor, and an altered mental health status that may be regarded as a 
central inhibitory mechanism of the parasympathetic innervation of the salivary glands.  
 Our group has previously demonstrated the production of anti-m3AChR antibodies in 
the majority of pSS patients (16, 17) by means of an ELISA method involving the second 
extracellular loop of the human m3AChR as antigen. The presence of these autoantibodies has 
been confirmed also by other investigators, moreover further epitopes were proposed on the 
m3AChR as the targets of immune response in pSS, specifically on the third extracellular loop 
(20-22, 24, 78); however others have failed to confirm our results (27, 79, 80). The production 
of anti-m3AChR antibodies has not yet been examined in SLE and RA, however an 
overlapping SS occurs in a large proportion of these common systemic autoimmune diseases. 
Our present results appear to confirm that the second extracellular loop is antigenic not only 
in pSS, but also in some SLE and RA patients. In addition, our findings support the recent 
results that the third extracellular loop also contains antigenic sequences in a considerable 
proportion of all these patients groups. 
 The diagnostic efficiency of the different antigen preparation modes for ELISA was 
also assessed. We demonstrated that the GST-fusion construct is an appropriate mode of 
antigen presentation. Actually, anti-GST-YNIP directed against the third extracellular loop of 
the m3AChR has emerged as the diagnostically most useful antibody, as it discriminates the 
pSS, SLE and RA patient groups from each other and from the controls with the best balance 
of specificity and sensitivity. These autoantibodies occurred most frequently in pSS, and a 
decreasing prevalence was observed in the following order: SLE > RA > controls. It should be 
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noted that the putative functional significance of the anti- m3AChR autoantibodies is rather 
expected with regard to those potentially inhibitory antibodies that target and bind to the 
second extracellular loop, where the ligand-binding region is located. Moreover, our data 
provide no indication whether the presence of anti-m3AChR antibodies may be directly 
related to the pathogenesis of SS overlapping with SLE or RA. Therefore, further validation 
of these results on larger patient populations and potentially a more precise epitope mapping 
are needed to elucidate the exact epitope specificity and functional importance of these 
autoantibodies.  
The development of SS overlapping with different systemic autoimmune diseases, 
including SLE or RA is rather variable. The probability of sicca symptoms in RA has been 
suggested to be correlated with the cumulative disease activity and the degree of functional 
impairment, i.e. the burden of the chronic disease (81), while others did not find such 
associations (82). In the present work we have demonstrated new data about the correlates of 
sicca syndrome in SLE. Certain clinical and immunoserological characteristics – organic 
brain syndrome, stroke, nephritis, lymphopenia, and anti-SSA-positivity – displayed 
differences with borderline significance between the SLE patients with and without sicca 
syndrome. Manoussakis et al. presented similar results in a larger cohort of patients (11), and 
the concordant findings of a recent meta-analysis (83) also confirm the assessment of sicca 
syndrome in our SLE cohort. It has to be emphasized that although some of the investigated 
SLE and RA patients with sicca symptoms did not strictly meet the classification criteria of 
secondary SS, they can definitely be regarded as patients with SS in clinical practice. The 
main reason of the incomplete diagnostic confirmation is that very few patients underwent 
labial salivary gland biopsy once the diagnosis of SLE and RA had been verified, mostly 
because of the lack of specific therapeutic consequences, or anticoagulant therapy. However, 
all the sicca syndrome patients had definitive objective and subjective glandular dysfunctions, 
since they showed markedly and repeatedly low salivary and lachrymal flow rates and they 
consequently gave positive answers to the sicca questionnaire on at least two separate 
occasions.   
Regarding the psychosocial well-being, our study revealed marked differences in the 
SLE + sicca syndrome patients compared to those patients in whom sicca symptoms were not 
present. The sicca patients versus non-sicca patients presented a significantly higher 
occurrence of psychological dysfunction including lower vitality, a worse perception of their 
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mental health, difficulties in physical functions reflecting the disturbances of usual daily 
activities such as work, studies or household duties, and worse scores in the SF-36 composite 
index, which indicates a lower overall level of mental well-being. The correlation of salivary 
dysfunction and the worse health-related quality of life has similarly been addressed 
previously (84). Our results suggest an association between the insufficient psychological 
parameters and the evolution of sicca symptoms, however this study is not sufficient to draw 
conclusions of causal relationships. Nevertheless, the chronic stress has been shown to have 
direct impact on saliva production, leading to chronic xerostomia (33, 85), and the salivary 
levels of cortisol and chromogranin A have also been found elevated in patients with low 
salivary flow rates (31, 32, 34). The mental alterations based on chronic stress, depression and 
the distress associated with SLE (35) may further impair the salivary gland function in 
addition to the immune-mediated mechanisms, and are factors that should be addressed during 
the care of these patients. 
In summary, the presented results have revealed a probably polyclonal autoimmune 
reaction to multiple epitopes on the m3AChR in SLE, but also in RA similarly to that in pSS. 
Our data indicate that the fusion of these antigenic peptides to GST may be useful in the 
development of a laboratory test for the diagnosis of SS both in primary and in overlapping 
cases. Furthermore, a dominant stress response and a deteriorated psychosocial well-being are 
suggested as contributors to the pathogenesis of SS in SLE. 
 
5.2. Investigation of the risk of the development of non-thromboembolic organ 
manifestations in systemic lupus erythematosus associated with antiphospholipid syndrome 
 
The disease course of SLE is highly variable with a wide spectrum of organ 
involvements ranging from mild, intermittent symptoms to life-endangering flares or a 
frequently relapsing clinical picture. The burden of the disease is greater when major 
manifestations occur, e.g. central nervous system, cardiac, pulmonary and renal symptoms. In 
view of the heterogeneity of SLE, it is important to identify prognostic clinical, demographic 
and laboratory parameters that would facilitate the prediction of the disease outcome in a 
condition in which a precise early assessment and risk-stratification are crucial to prevent life-
threatening complications. Any parameter of predictive value with regard to the severity of 
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the disease is highly informative for both the patient and the treating physician to decide on 
the appropriate treatment, including immunosuppressive agents.  
The assessment of specific autoantibody positivities (86-89) and some demographic 
parameters (e.g. age at onset, gender) (90-95) are useful in defining the prognosis of SLE. The 
development of various organ manifestations is related to the production of certain 
autoantibodies. Prominent examples are the anti-C1q antibodies, that indicate the appearance 
of nephritis (87), and anti-ribosomal-P antibodies that are associated with neuropsychiatric 
SLE (88, 89). Screening for these autoantibodies facilitates the early recognition of the related 
serious disease manifestations, and this may help prevent irreversible organ damage. The 
detection of APAs is of utmost importance in the determination of thromboembolic risk, 
hence the treatment guidelines of patients with such autoantibody positivity propose 
preventive platelet aggregation inhibitor therapy even without previous thrombotic events (77, 
96). The presence of APAs not only predisposes to the development thrombosis and 
accelerated atherosclerosis (97), but has also been verified to be associated with higher lupus-
related organ damage (51) and a poorer survival (2, 51).  
Our knowledge of the APS-specific symptoms is well established in SLE, however the 
impact of an associated APS on the other lupus-related morbidities has not been sufficiently 
studied to date. No detailed analysis is available regarding the contribution of APS to the risk 
of non-thromboembolic disease manifestations in SLE. In our investigations, we have 
obtained new information on the disease course of SLE, as we have detected that several non-
thromboembolic SLE-specific morbidities present more frequently in relation to APS. 
Similarly to the previous literature data, our results also showed that a significantly higher 
proportion of the APA-positive than of the APA-negative SLE patients developed Coombs-
positive haemolytic anaemia, thrombopenia or endocarditis. Nevertheless, our studies 
revealed remarkable differences in the clinical presentation of SLE when it was complicated 
by APS. In these patients various non-thromboembolic symptoms, including pleuritis, 
interstitial lung disease, myocarditis, nephritis and organic brain syndrome occurred 
significantly more often than in the absence of APS.  
The presented assessements verify that SLE patients with APS are at a higher overall 
mobidity risk and they are predisposed to more severe SLE disease course. The total number 
of major organ manifestations and the total number of the organ manifestations that have ever 
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occurred in an individual patient were both higher in the SLE + APS patients than in those 
without APS. In contrast, the presence of APA autoantibodies alone was accompanied only by 
an increased incidence of the above-mentioned organ involvements. 
The treatment of active SLE requires widespread experience and expert knowledge, 
but when APS is complicating the clinical picture it implies further challenges. The presented 
results indicate that SLE patients with APS frequently need specific and intense 
immunosuppressive therapies in addition to the long-term anticoagulant treatment. The 
management of these patients involved significantly more often the administration of 
immunosuppressive drugs including i.v. corticosteroid, i.v. cyclophosphamide and 
azathioprine than that of the non-APS patients.  
Summarizing our findings, when SLE is associated with APA production or with APS, 
the risk of the development of non-thromboembolic disease manifestations is higher, further 
influencing the clinical picture of SLE in addition to the APA-related symptoms. The burden 
of the disease is even greater regarding the fact that APS usually appears in young or middle-
aged SLE patients (98), and this determines a predisposition to more extensive organ damage 
during a longer disease course with enhanced disease severity. These characteristics and our 
results indicate that screening for APA autoantibodies is necessary at the time of the diagnosis 
of SLE. The higher morbidity and mortality rate of these patients warrants close attention to 
the potential presentation of nephritis, interstitial lung disease or neuropsychiatric 
manifestations, thereby providing opportunity to prevent life-threatening organ involvements 
and complications with the appropriate therapy. 
 
5.3. Investigation of the role of Galectin-1 in the apoptosis of T cells in systemic lupus 
erythematosus 
 
Gal-1 has been proposed as a possible candidate for immunosuppressive therapy in 
many earlier studies (63-69, 99), and the impaired Gal-1 expression has emerged as an 
important pathogenetic factor in the development of various immune-mediated diseases. The 
previous rodent experiments suggested a correlation between Gal-1 deficiency and lupus 
pathology, however the confirmation of this hypothesis in human disease is still lacking, and 
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the exact role of Gal-1 in the facilitation of the development of autoimmunity remained to be 
elucidated. Therefore we focused on the investigation of the impact of Gal-1 on the T cell 
pathophysiology in SLE. 
It has been shown that in physiological conditions T cells express Gal-1 upon 
activation, and the apoptotic effect of exGal-1 on activated T cells has also been described 
(54, 55, 57, 61, 100). Even though the signaling pathways responsible for this effect have 
largely been mapped (57, 58, 101-103), the exact mechanism by which the T cells are 
sensitized to exGal-1 driven apoptosis remained to be clarified. Blaser et al. have proposed 
that the apoptotic effect of exGal-1 on T cells might stem from an autocrine loop that is 
created by secretion of the protein (61), however Gal-1 is normally present in the serum only 
in very low quantities (several ng/ml) which is far below the apoptosis inducing concentration 
of the soluble protein (55, 100, 104). The previous results of our group have shown that Gal-1 
produced in activated T cells is not secreted to the extracellular space in any detectable 
amount, thus excluding the possibility of rebinding of this protein to cell surface 
glycoconjugates.  
The intracellular form of Gal-1 has not yet been implicated in the process of exGal-1-
related apoptosis, therefore our group intended to examine whether the intracellular, de novo 
expressed Gal-1 plays a role in the eventual fate of T cells. The studies were performed on a 
Gal-1 transgenic Jurkat model system and on wild type versus Gal-1 knockout murine 
activated T cells. The co-culture based experiments were designed specifically to create a 
physiologically more accurate environment to study the cytotoxic effect of cell-bound exGal-
1 in its native form (55). The analysis of Gal-1 producing and non-producing Jurkat clones 
and murine activated T cells co-cultured with cell-bound exGal-1 showed that Gal-1 deficient 
cells exhibited significantly lower susceptibility to apoptosis than did the Gal-1 expressing 
counterparts. The modulating effect of inGal-1 content on the apoptotic reaction of cells to 
exGal-1 was a novel finding, however the underlying exact mechanism remained to be 
elucidated.  
Based on these previous results the aim of this work was to investigate the role of Gal-
1 in the apoptosis of T cells under pathologic autoimmune conditions in SLE. We analyzed 
the sensitivity of SLE T cells to the exGal-1-mediated apoptotic signal. Since lupus T cells 
show mixed characteristics of activated and anergic cells and the inGal-1 content is crucial in 
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this mechanism, it is important to assess the ability of these cells to express Gal-1 upon 
activation. The severity of the disease might also influence this process. Our group has 
recently demonstrated that in active phase of the disease, activated SLE T cells in general 
contained significantly lower levels of Gal-1 mRNA than healthy controls, and after 
successful treatment, the T cells of the same SLE patients produced significantly more Gal-1 
mRNA, thus regaining corresponding levels to that of healthy controls.  
Our findings on the Gal-1 triggered apoptotic reactivity of activated SLE T cells 
revealed the expected outcome analogous to that in the preceding experiments. T cells of 
active lupus patients showed nearly no sensitivity to the cytotoxic effect of exGal-1, while the 
immunosuppressant therapy restored the T cells’ ability to undergo apoptosis induced by 
exGal-1. These cured lupus T cells behaved similarly to the T cells from healthy controls in 
the apoptosis assays. While we could not find a significant direct correlation between the 
exact level of inGal-1 mRNA in SLE T cells and their susceptibility to apoptosis, it is 
noteworthy that the observed tendencies and the apparent favorable effect of 
immunosuppressive therapy still indicate an association between diminished Gal-1 expression 
and the consequent downregulation of apoptosis in lupus T cells. 
Neither the apoptotic disturbances of SLE T cells, nor the individual values of the Gal-
1 mRNA levels correlated with particular parameters of the disease activity such as SLEDAI-
2K scores, anti-dsDNA antibody titers or ESR. This finding is possibly influenced by the 
relatively low number of studied patients, and by the fact that SLE has widespread 
immunological and clinical manifestations, which can hardly be reflected by disitinct single 
characteristics of the disease. Moreover, our findings do not provide information on how the 
Gal-1 deficiency modulates the clinical picture of SLE. 
In conclusion, we demonstrated that inGal-1 regulates the responsiveness of activated 
T cells to the apoptosis-inducing effect of exGal-1 in SLE similarly to the physiological 
process. The analysis of activated T cells from SLE patients shows a clear diminution in Gal-
1 expression and concomitant resistance to exGal-1 triggered apoptosis. These findings serve 
as potential novel markers to SLE pathogenesis. Gal-1 related apoptotic disturbances might 
contribute to immunoregulatory dysfunction and enhanced T cell activity in SLE pathology. 
This mechanism is supported by the finding that successful immunosuppressive therapy 
results in restoration of the level of Gal-1 as well as the apoptotic sensitivity of SLE T cells. 
In addition to the defective Gal-1 expression, impaired binding of exGal-1 on T cells or the 
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presence of anti-Gal-1 autoantibodies might also contribute to this novel pathogenetic 
mechanism, therefore further studies are needed to assess their roles.  
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